Free shipping on all orders over $ 500

Tofacitinib citrate

Cat. No. M3616
Tofacitinib citrate  Structure

CP-690550 citrate

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mg USD 36  USD40 In stock
50mg USD 81  USD90 In stock
100mg USD 108  USD120 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

Tofacitinib citrate inhibits IL-2-mediated human T cell blast proliferation and IL-15-induced CD69 expression with IC50 of 11 nM and 48 nM, respectively. Tofacitinib citrate prevents mixed lymphocyte reaction with IC50 of 87 nM. Tofacitinib citrate inhibits interleukin-6-induced phosphorylation of STAT1 and STAT3 with IC50 of 23 nM and 77 nM, respectively. Tofacitinib citrate decrease a delayed-type hyper-sensitivity response and extended cardiac allograft survival in murine models. CP-690,550 induced a significant pro-apoptotic effect on murine FDCP-EpoR cells carrying JAK2(V617F), whereas a lesser effect was observed for cells carrying wild-type JAK2.

Product Citations
Cell Experiment
Cell lines FDCP-EpoR JAK2WT and JAK2V617F cell lines
Preparation method Using identical culture conditions for both FDCP-EpoR JAK2WT and JAK2V617F cell lines perform determination of growth inhibition by Tofacitinib citrate is performed. Briefly, culturing 1 × 105 cells/mL in 96-well flat-bottom plates at 37 °C in a humidified 5% CO2 atmosphere using RPMI 1640 supplemented with 1.25% FCS, and 5% WEHI supernatant. It's necessary to prevent binding between Tofacitinib citrate and serum proteins to decrease FCS concentration . Terminating growth inhibition assays by addition of 20 μL CellTiter96 One Solution Reagent. Incubating Flat-bottom plates for an additional 3 hours for MTT assay. Determining absorbance at 595 nm on a BioTek Synergy-HT microplate reader. Results are the average standard deviation of three independent determinations.
Concentrations 0-4 μM
Incubation time 72 hours
Animal Experiment
Animal models Mauritius-origin adult cynomolgus monkeys
Formulation 0.5% methylcellulose in distilled water
Dosages 10, 30 mg/kg/d
Administration Oral gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 504.49
Formula C22H28N6O8
CAS Number 540737-29-9
Purity 98.93%
Solubility DMSO >30 mg/mL
Water 2 mg/mL
Storage at -20°C

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Manshouri T, et al. Cancer Sci. 2008 Jun;99(6):1265-73. PMID: 18482053.

Related JAK Products
Delphinidin chloride

Delphinidin (chloride) is an anthocyanidin, a natural plant pigment which can modulate JAK/STAT3 and MAPKinase signaling to induce apoptosis in HCT116 cells.


AZD4205 is a novel potent and selective janus kinase 1 (JAK1) inhibitor, with IC50 value of 73 nM.


PF-06826647, also known as Tyk2-IN-8, is a selective and orally administered tyrosine kinase 2 (TYK2) inhibitor, with IC50 of 17 nM.

PF-06700841 tosylate

PF-06700841 (Brepocitinib) tosylate is a dual inhibitor of JAK1 and TYK2, with IC50 values of 17 nM and 23 nM, respectively.

JAK3-IN-6 (Compound 2)

JAK3-IN-6 (Compound 2) CAS#: 1443235-95-7 is a potent and highly selective JAK3 inhibitor, with an IC50 of 0.15 nM.

Abmole Inhibitor Catalog 2017

Keywords: Tofacitinib citrate , CP-690550 citrate supplier, JAK, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.